Value of mitomycin C in chronic angle-closure glaucoma patients with glaucoma and cataract
Author:
Corresponding Author:

Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM: To investigate the value of mitomycin C(MMC)in chronic angle-closure glaucoma patients with glaucoma and cataract, and to provide reference for the clinical treatment.

    METHODS: Forty patients with chronic angle-closure glaucoma and cataract patients were randomly divided into the observation group(MMC group)and the control group(NonMMC group). Phacoemulsification and trabeculectomy was used for the treatment. The treatment effects were compared.

    RESULTS: After treatment, the distance vision(corrected), peripheral anterior chamber depth, intraocular pressure and the number and types of the IOP drug of observation group were all better than those of the control group(all P<0.05). There was no statistically significant difference of the proportion of functional blebs of the two groups(P>0.05). The main complications after the treatment was shallow anterior chamber, in which the observation group was 1 case(5%)and the control group were 2 cases(10%)(P>0.05).

    CONCLUSION:MMC in chronic angle-closure glaucoma patients with glaucoma and cataract could improve the intraocular pressure, visual acuity and should be recommended for clinical treatment.

    Reference
    Related
    Cited by
Get Citation

Zhi-Hua He, Yan Li. Value of mitomycin C in chronic angle-closure glaucoma patients with glaucoma and cataract. Guoji Yanke Zazhi( Int Eye Sci) 2013;13(11):2311-2313

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:September 02,2013
  • Revised:October 23,2013
  • Adopted:
  • Online: October 28,2013
  • Published: